[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609809":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":33,"responsibleParty":106,"collaborators":11,"id":108,"slug":11,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":11,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":11,"studyType":120,"phases":121,"briefSummary":123,"conditions":124,"keywords":131,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},{"fullName":5,"class":6},"Rapport Therapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"RAP-219","EXPERIMENTAL",null,[13],"Drug: RAP-219",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","Participants will receive one RAP-219 0.125 mg capsule daily for 3 days followed by one 0.25mg tablet RAP-219 daily for 28 days, then one 0.75mg tablet daily for the remainder of the treatment period.",[9],[20],{"name":21,"affiliation":22,"role":23},"Imran Quraishi, MD","Yale University","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Daniela Moreno","CONTACT","(857) 323-9048","dmoreno@rapportrx.com",{"name":31,"role":27,"phone":28,"phoneExt":11,"email":32},"Beth Bowers","bbowers@rapportrx.com",[34,47,57,66,76,86,96],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":11},"Consultants in Epilepsy and Neurology, PLLC","RECRUITING","Boise","Idaho","83702","United States",{"type":42,"coordinates":43},"Point",[44,45],-116.20345,43.6135,{"lat":45,"lon":44},{"facility":48,"status":36,"city":49,"state":50,"zip":51,"country":40,"cosmosGeoPoint":52,"geoPoint":56,"contacts":11},"Mayo Clinic","Rochester","Minnesota","55905",{"type":42,"coordinates":53},[54,55],-92.4699,44.02163,{"lat":55,"lon":54},{"facility":58,"status":36,"city":59,"state":59,"zip":60,"country":40,"cosmosGeoPoint":61,"geoPoint":65,"contacts":11},"NYU Langone Comprehensive Epilepsy Center","New York","10016",{"type":42,"coordinates":62},[63,64],-74.00597,40.71427,{"lat":64,"lon":63},{"facility":67,"status":36,"city":68,"state":69,"zip":70,"country":40,"cosmosGeoPoint":71,"geoPoint":75,"contacts":11},"Cleveland Clinic Foundation","Cleveland","Ohio","44195",{"type":42,"coordinates":72},[73,74],-81.69541,41.4995,{"lat":74,"lon":73},{"facility":77,"status":36,"city":78,"state":79,"zip":80,"country":40,"cosmosGeoPoint":81,"geoPoint":85,"contacts":11},"University of Pennsylvania - Department of Neurology","Philadelphia","Pennsylvania","19104",{"type":42,"coordinates":82},[83,84],-75.16362,39.95238,{"lat":84,"lon":83},{"facility":87,"status":36,"city":88,"state":89,"zip":90,"country":40,"cosmosGeoPoint":91,"geoPoint":95,"contacts":11},"Vanderbilt University Medical Center","Nashville","Tennessee","37232",{"type":42,"coordinates":92},[93,94],-86.78444,36.16589,{"lat":94,"lon":93},{"facility":97,"status":36,"city":98,"state":99,"zip":100,"country":40,"cosmosGeoPoint":101,"geoPoint":105,"contacts":11},"Baylor College of Medicine","Houston","Texas","770300",{"type":42,"coordinates":102},[103,104],-95.36327,29.76328,{"lat":104,"lon":103},{"type":107,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100609809",false,"NCT07219407","A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures","An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures","Inclusion Criteria:\n\n* Completion of the associated parent study (RAP-219-FOS-201) treatment period with acceptable tolerability, per Investigator.\n* Diagnosis of refractory focal epilepsy\n* Stable RNS(c) system settings\n* A demonstrated history of compliance with RNS(c) system data interrogation and upload\n* Good overall health other than focal epilepsy, per Investigator.\n* BMI ≥ 18 kg\u002Fm\\^2 and ≤ 45 kg\u002Fm\\^2\n* Willing and able to adhere to all aspects of the protocol.\n\nExclusion Criteria:\n\n* Known of hypersensitivity to RAP-219\n* Any clinically unstable or serious medical, neurological (other than epilepsy), psychological, or behavioral problem; laboratory or ECG finding that would increase participant risk or should otherwise exclude the patient from participation, as assessed by Investigator\n* Pregnancy, lactation, or individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods","ALL","18 Years","70 Years",{"count":118,"type":119},30,"ESTIMATED","INTERVENTIONAL",[122],"PHASE2","This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.",[125,126,127,128,129,130],"Focal Epilepsy","Epilepsy","Refractory Focal Epilepsy","Seizure","Focal Seizure","Focal Onset Seizure",[132,126,133,134],"Focal Seizures","RNS","Long episode","2026-01-22",{"date":137,"type":138},"2026-01-23","ACTUAL",{"date":140,"type":138},"2025-12-15",{"date":142,"type":119},"2028-02-03",{"name":5,"class":6},7]